Robin A. Fairhurst
Novartis (Switzerland)(CH)Novartis Foundation(CH)
Publications by Year
Research Areas
Fibroblast Growth Factor Research, Kruppel-like factors research, Epigenetics and DNA Methylation, Receptor Mechanisms and Signaling, Chemical Synthesis and Reactions
Most-Cited Works
- → Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation(2013)463 cited
- → In Vitro and in Vivo Pharmacological Characterization of 5-[(R)-2-(5,6-Diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1 H-quinolin-2-one (Indacaterol), a Novel Inhaled β2 Adrenoceptor Agonist with a 24-h Duration of Action(2006)161 cited
- → Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4(2020)110 cited
- → Effect of indacaterol, a novel long-acting β2-agonist, on isolated human bronchi(2006)107 cited
- → Observed Drug-Receptor Association Rates Are Governed by Membrane Affinity: The Importance of Establishing “Micro-Pharmacokinetic/Pharmacodynamic Relationships” at the β2-Adrenoceptor(2014)104 cited
- → FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer(2019)